Last reviewed · How we verify
DTaP-IPV-Hib-HepB vaccine — Competitive Intelligence Brief
phase 3
vaccine
Immunology
Biologic
Live · refreshed every 30 min
Target snapshot
DTaP-IPV-Hib-HepB vaccine (DTaP-IPV-Hib-HepB vaccine) — Sanofi Pasteur, a Sanofi Company. This combination vaccine stimulates the immune system to produce antibodies against diphtheria, tetanus, pertussis, poliomyelitis, Haemophilus influenzae type b, and hepatitis B pathogens.
Comparator set (6 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| DTaP-IPV-Hib-HepB vaccine TARGET | DTaP-IPV-Hib-HepB vaccine | Sanofi Pasteur, a Sanofi Company | phase 3 | vaccine | ||
| Comirnaty | BNT162b2 (tozinameran) | Pfizer Inc. | marketed | vaccine | SARS-CoV-2 virus | 2021-08-23 |
| Prevnar 20 | pneumococcal 20-valent conjugate vaccine (PCV20) | Pfizer Inc. | marketed | Pneumococcal conjugate vaccine | Streptococcus pneumoniae capsular polysaccharides (20 serotypes) | 2021-06-08 |
| Meningococcal B (Bexsero) | Meningococcal B (Bexsero) | University of Sao Paulo General Hospital | marketed | Recombinant protein vaccine | Meningococcal serogroup B surface antigens (recombinant Neisseria meningitidis proteins) | |
| Fluvirin(TIVf) | Fluvirin(TIVf) | Novartis | marketed | Inactivated influenza vaccine | ||
| EV71 +SIV | EV71 +SIV | Zhejiang Provincial Center for Disease Control and Prevention | marketed | Inactivated viral vaccine | ||
| Meningococcal C | Meningococcal C | Wyeth is now a wholly owned subsidiary of Pfizer | marketed | Conjugate vaccine | Neisseria meningitidis serogroup C polysaccharide capsule |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
- — Prevnar 20 · US 8,895,024 · Composition of matter · US
- — Prevnar 20 · US 10,279,033 · Method of use · US
Sponsor landscape (vaccine class)
- Pfizer · 20 drugs in this class
- Sanofi Pasteur, a Sanofi Company · 20 drugs in this class
- GlaxoSmithKline · 12 drugs in this class
- Merck Sharp & Dohme LLC · 12 drugs in this class
- Centers for Disease Control and Prevention · 9 drugs in this class
- Zhejiang Provincial Center for Disease Control and Prevention · 7 drugs in this class
- Jiangsu Province Centers for Disease Control and Prevention · 6 drugs in this class
- Beijing Center for Disease Control and Prevention · 6 drugs in this class
- International Centre for Diarrhoeal Disease Research, Bangladesh · 5 drugs in this class
- Sinovac Biotech Co., Ltd · 4 drugs in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- DTaP-IPV-Hib-HepB vaccine CI watch — RSS
- DTaP-IPV-Hib-HepB vaccine CI watch — Atom
- DTaP-IPV-Hib-HepB vaccine CI watch — JSON
- DTaP-IPV-Hib-HepB vaccine alone — RSS
- Whole vaccine class — RSS
Cite this brief
Drug Landscape (2026). DTaP-IPV-Hib-HepB vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/dtap-ipv-hib-hepb-vaccine. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab